Sinzinger H, Wirthumer-Hoche C
Wien Klin Wochenschr. 1985 Sep 27;97(18):720-2.
Earlier investigations have demonstrated that buflomedil, a substance which is successful in the clinical treatment of peripheral vascular disease, exerts an inhibitory effect on ADP-induced aggregation ex vivo and in vitro. In the presented study the effect of buflomedil on platelets is investigated. Clinically widely used platelet function tests were performed after a single oral dose of buflomedil (300 mg) to healthy volunteers. Again, an ex vivo inhibition of ADP-induced aggregation was confirmed. None of the other parameters examined was influenced by the administered drug, such as plasma thromboxane B2, the platelet proteins, the platelet sensitivity to antiaggregatory prostaglandins and the prostacyclin synthesis stimulating plasma factor.
早期研究表明，丁咯地尔这种在临床治疗外周血管疾病中取得成功的物质，在体内外均对ADP诱导的聚集发挥抑制作用。在本研究中，对丁咯地尔对血小板的作用进行了研究。对健康志愿者单次口服丁咯地尔（300毫克）后，进行了临床上广泛使用的血小板功能测试。再次证实了对ADP诱导聚集的体外抑制作用。所检测的其他参数均未受给药药物的影响，如血浆血栓素B2、血小板蛋白、血小板对抗聚集前列腺素的敏感性以及刺激前列环素合成的血浆因子。
